An Invitation from America
"Director Shen, from a purely chemical perspective, C01C-2 is a success." Old Yan was still very excited, after all, there were many innovations in this project.
"Synthesizing a new compound depends 30% on experience, 30% on technique, and the rest on luck. I've been quite lucky." Shen Qi asked Old Yan and Cheng Haonan to do a few more sets of experiments and then compile a report.
C01C is a benzothiazide compound that theoretically has the potential to treat diabetes, and this has been verified in rat experiments.
Because the results were unsatisfactory in the dog experiments, Shen Qi improved the chemical structure of C01C. C01C-2 still uses benzothiazide as the parent core, but the side chains were optimized.
According to Shen Qi's research, C01C-2 is also a compound for treating Type II Diabetes, and it will be verified in animal experiments.
Diabetes is recognized as the most widespread epidemic disease in the world, with 200 million people suffering from the disease today, and the number is expected to double within ten years.
Type II Diabetes is a chronic polysaccharidosis accompanied by insulin antibodies, which prevents the pancreas from producing enough insulin to control blood sugar levels.
Many current treatments for Type II Diabetes are often unsatisfactory due to their side effects.
Therefore, Shen Qi believes that their research result C01C-2 has very important scientific research value.
At the level of mechanism theory, there is still a puzzle that is troubling Shen Qi.
C01C-2 can be classified as a non-ATP-competitive inhibitor of glycogen synthase kinase-3β. Glycogen synthase kinase-3β is a multifunctional protein kinase and a target associated with various diseases, such as diabetes, Alzheimer's disease, cancer, and immune diseases.
Why are the CO1C and CO1C-2 synthesized by Shen Qi and his team primarily targeted at diabetes, rather than other diseases?
How can researchers precisely target specific diseases to develop corresponding inhibitors?
This requires ongoing research to find the true manipulation mechanism.
Ou Ye did not have diabetes; what troubled her for a long time was an immune disease and anemia.
Recently, Ou Ye has been feeling unwell again; she feels weak and listless. Shen Qi noticed this and felt anxious.
"No matter what, let's finish the clinical trials of C01C-2 first." Shen Qi was determined to complete the follow-up testing of C01C-2. Although C01C-2 was designated as a drug for Type II Diabetes, Shen Qi believed that in the process of in-depth research, there was hope to find the true control mechanism of glycogen synthase kinase-3β, accumulating valuable experience and data for the next compound targeting the immune diseases of Ou Ye.
The paper C01C-2, titled "Design, Synthesis and Bioactivity Evaluation of Non-ATP Competitive Inhibitors of Benzothiazinone Glycogen Synthetase Kinase-3β", was published in the internationally renowned chemistry journal, * Journal of the American Chemical Society *.
The article mentions that our research group designed a synthetic route using a novel molecular hybridization method to obtain a novel benzothiazinone compound, and studied its inhibitory activity and kinetic mode of action on glycogen synthase kinase-3β. The study indicates that this compound has certain reference value for the treatment of Type II Diabetes.
The American Chemical Society paid close attention to the research findings of Shen Qi's chemistry research group, stating that the paper discusses a new synthetic reaction that has significant academic value.
"Professor Shen, we hope you can come to the United States. We will organize a high-level academic conference for you." The president of the American Chemical Society sincerely invited Shen Qi to the United States for academic exchange.
Shen Qi said on the phone, "I will contact you again after the time is confirmed."
Besides the American Chemical Society, other organizations that invited Shen Qi to the United States include the American Mathematical Society, the American Physical Society, the Chinese Academy of Sciences, Princeton University, Harvard University, and Caltech.
Shen Qi left the United States for five years and did not return to the United States during that time.
This time, Shen Qi changed his mind and decided to go to the United States.
Princeton is where Shen Qi once studied and worked, and he still holds the title of Honorary Professor of Mathematics at Princeton. It is inappropriate for him to repeatedly refuse friendly invitations from his alma mater.
The Chinese Academy of Sciences awarded Shen Qi the title of Foreign Associate, which he accepted, but he still has to go to the United States to receive the certificate when he has time.
Shen Qi has ideas in the field of chemistry.
According to the system settings, to advance from Chemistry Level 12 to Level 13, Shen Qi must obtain at least one international Chemistry Prize and 4 million Academic Points.
Winning the Nobel Prize for the second time, being awarded the title of foreign academician of the United Kingdom, the United States, France, Russia and other countries, and becoming a dual academician of China, these achievements have brought Shen Qi tens of millions of academic points. He is not lacking in academic points now, but only in fulfilling the special conditions set by the system.
Winning the Nobel Chemistry Prize based on a novel organic reaction might be quite difficult.
If Shen Qi's C01C-2 successfully passes several phases of clinical trials and is proven to be the best diabetes drug to date, then he will have the opportunity to obtain Novartis approval.
Alternatively, if Shen Qi discovers the true mechanism of action of glycogen synthase kinase-3β inhibitors and can establish a theoretical system of mechanisms to precisely target the target, then his chances of winning the Nobel Chemistry Prize or Physiology or Medicine are even higher.
This is not something that can be achieved overnight, after all, chemistry is only at the 12th grade level.
Shen Qi has won almost every award in the Mathematics Community and Physics Community, and he has won them repeatedly, including the Nobel Prize in Physics twice.
Now, it's time to take a look at the awards in the field of chemistry.
The American Chemical Society has several international Chemistry Prize, and Shen Qi had some thoughts about them, but he couldn't express them too openly, after all, he was a famous scientist with status and position.
"Sir, I need to go to the United States for academic exchange. Please approve."
Leader: "Professor Shen, do you really need to go to the United States in person?"
"Boss, I have no choice. I have some academic friends in the US, and I have to go see them. They're all elderly gentlemen in their eighties and nineties. If I don't go now, I'll never have the chance again." Shen Qi spoke from the heart. Of his friends at Princeton, one had recently passed away, and two others were bedridden. "These titans of American academia have given me a lot of academic guidance and help. I should go to the US to visit these senior figures, my teachers, and my friends."
"Respecting teachers and valuing education is a virtue, and Professor Shen did the right thing." After careful consideration, the leaders agreed to Shen Qi's trip to the United States for a friendly academic visit.
"You'd better not go to the United States alone," the leader suggested.
"Okay, I originally wanted to lead a team to the United States," Shen Qi said, and immediately began organizing his academic exchange team to the United States.